ESMO: Bayer hopes to expand Nubeqa's prostate cancer reach with chemo-free regimen

Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of chemotherapy.

Bayer plans to seek the FDA’s blessing for Nubeqa plus androgen deprivation therapy (ADT) in mHSPC after the phase 3 ARANOTE trial showed that the combination led to a statistically significant 46% reduction in the risk of progression or death compared with ADT alone.